Study Details
Design, interventions, and primary outcomes
About This Study
Investigating the Association Between Corticosteroid Use and Improvement in Doxorubicin Liposome-Induced Cutaneous Toxicity: Exploring the Feasibility and Mechanisms of Corticosteroids in Mitigating Liposomal Doxorubicin-Related Dermatologic Adverse Effects.
Design
Interventions / Regimen
- Drug: Dexamethasone (12mg d1) — dexamethasone 12mg d1, PO/IV;
- Drug: Dexamethasone (2mg QD, d1-5,) — dexamethasone 12mg QD, d1-5, PO/IV.
- Drug: Doxorubicin hydrochloride liposome injection — Liposomal doxorubicin at a dose of 35 mg/m², given via intravenous (IV) infusion every 2 weeks (q2w) or every 3 weeks (q3w).
- Drug: Cyclophosphamide — Cyclophosphamide 600 mg/m² administered by intravenous infusion every 2 weeks (q2w) or every 3 weeks (q3w).
Primary Outcomes
- Number of participants with hand-foot syndrome (HFS) as assessed by CTCAE v5.0 in the high-dose dexamethasone group (17 months)
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-07
Completion: 2027-01-30
Sex: ALL
Volunteers: false
Enrollment: 182 (ESTIMATED)
- Drug: Dexamethasone (12mg d1) — dexamethasone 12mg d1, PO/IV;
- Drug: Dexamethasone (2mg QD, d1-5,) — dexamethasone 12mg QD, d1-5, PO/IV.
- Drug: Doxorubicin hydrochloride liposome injection — Liposomal doxorubicin at a dose of 35 mg/m², given via intravenous (IV) infusion every 2 weeks (q2w) or every 3 weeks (q3w).
- Drug: Cyclophosphamide — Cyclophosphamide 600 mg/m² administered by intravenous infusion every 2 weeks (q2w) or every 3 weeks (q3w).